Systematic Review and Meta-Analysis of Combination Therapy with Cholinesterase Inhibitors and Memantine in Alzheimer's Disease and Other Dementias

被引:34
|
作者
Muayqil, Taim [1 ]
Camicioli, Richard [2 ]
机构
[1] King Saud Univ, Div Neurol, Riyadh, Saudi Arabia
[2] Univ Alberta, Div Neurol, Edmonton, AB, Canada
来源
DEMENTIA AND GERIATRIC COGNITIVE DISORDERS EXTRA | 2012年 / 2卷 / 01期
关键词
Dementia; Alzheimer; Dementia therapy; Combination treatment; Cholinesterase inhibitors; Memantine; Side effects;
D O I
10.1159/000343479
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: N-methyl-D-aspartic acid antagonists (memantine) and cholinesterase inhibitors (ChEIs) are the only two approved classes of drugs to treat dementia; this paper explores the evidence for using these two treatments in combination. Objective: To determine the efficacy and safety of using combination therapy with memantine and a ChEI to treat dementia in comparison to monotherapy with either memantine or a ChEI. Methods: In March 2012, we systematically searched MEDLINE/PubMed, EMBASE, Cochrane library, and grey literature databases. All study types were included, except for case series or reports, which looked at combination therapy versus monotherapy in various dementing disorders. Data was pooled for blinded ran-domized controlled trials (RCTs) only; mean differences and standardized mean differences were used to determine effect sizes. Results: Thirteen studies were included in this review; 3 were blinded RCTs, with a total of 971 Alzheimer's disease (AD) patients, which were included into the meta-analysis. No papers were found that primarily addressed combination therapy in other dementias. In the meta-analysis, small but statistically significant effect sizes were seen in favor of combination therapy among patients with moderate to severe AD on the scales of cognition (0.45-0.52; p < 0.0001), scales of functional outcomes (0.23-0.3; p < 0.01), and the neuropsychiatric inventory (3.7-4.4; p < 0.0001). Among the open-label studies, 3 out of 6 suggested benefits, as did the 4 included cohort studies. However, the high risk of bias encountered in the latter two study designs limits deducing any conclusions about benefit. Conclusion: Although there were statistically significant changes in favor of combination therapy in moderate to severe AD, heterogeneity in scales and patient characteristics exists. However, it is unclear if clinically significant outcomes can be achieved using the combination therapy. More studies are required before a recommendation for combination therapy can be made. Copyright (C) 2012 S. Karger AG, Basel
引用
收藏
页码:546 / 572
页数:27
相关论文
共 50 条
  • [21] Intelligent Assistive Technology for Alzheimer's Disease and Other Dementias: A Systematic Review
    Ienca, Marcello
    Fabrice, Jotterand
    Elger, Bernice
    Caon, Maurizio
    Pappagallo, Alessandro Scoccia
    Kressig, Reto W.
    Wangmo, Tenzin
    JOURNAL OF ALZHEIMERS DISEASE, 2017, 56 (04) : 1301 - 1339
  • [22] Cholinesterases in Alzheimer’s disease and Cholinesterase inhibitors in Alzheimer therapy
    Z. Rakonczay
    I. Kovács
    Acta Biologica Hungarica, 1998, 49 (1): : 55 - 70
  • [23] Cholinesterases in Alzheimer's disease and cholinesterase inhibitors in Alzheimer therapy
    Rakonczay, Z
    Kovács, I
    ACTA BIOLOGICA HUNGARICA, 1998, 49 (01): : 55 - 70
  • [24] Different durations of cognitive stimulation therapy for Alzheimer's disease: a systematic review and meta-analysis
    Chen, Juexuan
    Duan, Yuting
    Li, Huanjie
    Lu, Liming
    Liu, Jihong
    Tang, Chunzhi
    CLINICAL INTERVENTIONS IN AGING, 2019, 14 : 1243 - 1254
  • [25] Efficacy and Safety of Cholinesterase Inhibitors for Mild Cognitive Impairment: A Systematic Review and Meta-Analysis
    Matsunaga, Shinji
    Fujishiro, Hiroshige
    Takechi, Hajime
    JOURNAL OF ALZHEIMERS DISEASE, 2019, 71 (02) : 513 - 523
  • [26] Cholinesterase Inhibitors for Treatment of Psychotic Symptoms in Alzheimer Disease and Parkinson Disease A Meta-analysis
    d'Angremont, Emile
    Begemann, Marieke J. H.
    van Laar, Teus
    Sommer, Iris E. C.
    JAMA NEUROLOGY, 2023, 80 (08) : 813 - 823
  • [27] Midlife Hypertension and Alzheimer's Disease: A Systematic Review and Meta-Analysis
    Lennon, Matthew J.
    Makkar, Steve R.
    Crawford, John D.
    Sachdev, Perminder S.
    JOURNAL OF ALZHEIMERS DISEASE, 2019, 71 (01) : 307 - 316
  • [28] The Prevalence of Alzheimer's Disease in China: A Systematic Review and Meta-analysis
    Li, Kanglan
    Wei, Shouchao
    Liu, Zhou
    Hu, Li
    Lin, Jiajing
    Tan, Shiting
    Mai, Yingren
    Peng, Wanjuan
    Mai, Hui
    Hou, Qi
    Tu, Guifeng
    IRANIAN JOURNAL OF PUBLIC HEALTH, 2018, 47 (11) : 1615 - 1626
  • [29] Alzheimer's Disease: Efficacy of Mono- and Combination Therapy. A Systematic Review
    Knorz, Adrian L.
    Quante, Arnim
    JOURNAL OF GERIATRIC PSYCHIATRY AND NEUROLOGY, 2022, 35 (04) : 475 - 486
  • [30] Phosphodiesterase-5 inhibitors use and the risk of alzheimer's disease: a systematic review and meta-analysis
    Abouelmagd, Moaz Elsayed
    Abdelmeseh, Maickel
    Elrosasy, Amr
    Saad, Yousef Hesham
    Alnajjar, Asmaa Zakria
    Eid, Mahmoud
    Hassan, Atef
    Abbas, Abdallah
    NEUROLOGICAL SCIENCES, 2024, 45 (11) : 5261 - 5270